CHMFL-ABL/KIT-155

CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC50=81 nM), CSF1R (IC50=227 nM), DDR1 (IC50=116 nM), DDR2 (IC50=325 nM), LCK (IC50=12 nM) and PDGFRβ (IC50=80 nM) kinases. CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155) arrests cell cycle progression and induces apoptosis[1].

Product Specifications

CAS Number

[2081093-21-0]

Product Name Alternative

CHMFL-ABL-KIT-155

UNSPSC

12352005

Target

Apoptosis; Bcr-Abl; c-Kit; Discoidin Domain Receptor; PDGFR

Type

Reference compound

Related Pathways

Apoptosis; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/chmfl-abl-kit-155.html

Solubility

10 mM in DMSO

Smiles

O=C(N1CCC(OC2=CC(NC(C3=CC=C(CN4CCN(C)CC4)C(C(F)(F)F)=C3)=O)=CC=C2C)CC1)C5=CC=C(C)N=C5

Molecular Formula

C33H38F3N5O3

Molecular Weight

609.68

References & Citations

[1]Wang Q, et al. Discovery of 4-Methyl-N- (4- ((4-methylpiperazin-1-yl) methyl) -3- (trifluoromethyl) phenyl) -3- ((1-nicotinoylpiperidin-4-yl) oxy) benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding. J Med Chem. 2017 Jan 12;60 (1) :273-289.